Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

816 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial.
Galløe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamäki K, Junker A, Aarøe J, Abildgaard U, Ravkilde J, Engstrøm T, Jensen JS, Andersen HR, Bøtker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrøm SZ, Stephansen GB, Lassen JF; SORT OUT II Investigators. Galløe AM, et al. Among authors: jensen js. JAMA. 2008 Jan 30;299(4):409-16. doi: 10.1001/jama.299.4.409. JAMA. 2008. PMID: 18230778 Clinical Trial.
Field triage reduces treatment delay and improves long-term clinical outcome in patients with acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Pedersen SH, Galatius S, Hansen PR, Mogelvang R, Abildstrom SZ, Sørensen R, Davidsen U, Galloe A, Abildgaard U, Iversen A, Bech J, Madsen JK, Jensen JS. Pedersen SH, et al. Among authors: jensen js. J Am Coll Cardiol. 2009 Dec 8;54(24):2296-302. doi: 10.1016/j.jacc.2009.06.056. J Am Coll Cardiol. 2009. PMID: 19958965 Free article.
Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK, Engstroem T, Pedersen S, Jensen KS, Jensen JS. Iversen A, et al. Among authors: jensen ks, jensen js. J Interv Cardiol. 2011 Apr;24(2):105-11. doi: 10.1111/j.1540-8183.2010.00616.x. Epub 2010 Dec 22. J Interv Cardiol. 2011. PMID: 21175845 Free article. Clinical Trial.
Ten-year clinical outcome of patients treated with a drug-eluting stent in the proximal left anterior descending artery segment compared with patients stented in other non-left main coronary segments.
Kjøller-Hansen L, Bligaard N, Kelbæk H, Christiansen EH, Thuesen L, Hansen PR, Engstrøm T, Junker A, Abildgaard U, Lassen JF, Jensen JS, Jeppesen JL, Galløe AM. Kjøller-Hansen L, et al. Among authors: jensen js. EuroIntervention. 2018 Sep 20;14(7):764-771. doi: 10.4244/EIJ-D-18-00396. EuroIntervention. 2018. PMID: 29969425 Free article.
Long-term prognosis in an ST-segment elevation myocardial infarction population treated with routine primary percutaneous coronary intervention: from clinical trial to real-life experience.
Pedersen S, Galatius S, Mogelvang R, Davidsen U, Galloe A, Abildstrom SZ, Abildgaard U, Hansen PR, Bech J, Iversen A, Jorgensen E, Kelbaek H, Saunamaki K, Madsen JK, Jensen JS. Pedersen S, et al. Among authors: jensen js. Circ Cardiovasc Interv. 2009 Oct;2(5):392-400. doi: 10.1161/CIRCINTERVENTIONS.108.845636. Epub 2009 Aug 18. Circ Cardiovasc Interv. 2009. PMID: 20031748
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.
Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrøm T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrøm SZ, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Madsen M, Johnsen SP, Jensen LO, Sørensen HT, Thuesen L, Lassen JF; SORT OUT III study group. Rasmussen K, et al. Among authors: jensen lo, jensen js. Lancet. 2010 Mar 27;375(9720):1090-9. doi: 10.1016/S0140-6736(10)60208-5. Epub 2010 Mar 16. Lancet. 2010. PMID: 20231034 Clinical Trial.
3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents.
Maeng M, Tilsted HH, Jensen LO, Kaltoft A, Kelbæk H, Abildgaard U, Villadsen AB, Krusell LR, Ravkilde J, Hansen KN, Christiansen EH, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Madsen M, Thayssen P, Sørensen HT, Thuesen L, Lassen JF. Maeng M, et al. Among authors: jensen lo, jensen js. JACC Cardiovasc Interv. 2012 Aug;5(8):812-8. doi: 10.1016/j.jcin.2012.04.008. JACC Cardiovasc Interv. 2012. PMID: 22917452 Free article. Clinical Trial.
Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
Maeng M, Tilsted HH, Jensen LO, Krusell LR, Kaltoft A, Kelbæk H, Villadsen AB, Ravkilde J, Hansen KN, Christiansen EH, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Thuesen L, Madsen M, Thayssen P, Sørensen HT, Lassen JF. Maeng M, et al. Among authors: jensen lo, jensen js. Lancet. 2014 Jun 14;383(9934):2047-2056. doi: 10.1016/S0140-6736(14)60405-0. Epub 2014 Mar 14. Lancet. 2014. PMID: 24631162 Clinical Trial.
816 results